Journal of Internal Medicine 1992: Vol 232 Index

9 Pages·1992·1.7 MB·English

Journal of Internal Medicine 1992; 232: 545-549
Author Index
Aase O, see Rollag et al., 299 Bosello O, see Zamboni et al., 341
Agbedana EO, see Ahaneku et al., 489 Bothwell TH, see Lapinsky et al., 273
Agnarsson UT, Hardarson T, Hallgrimsson, Sigfusson N. The Bottiger LE. Minisymposium: Medical journals—today and
prevalence of hypertrophic cardiomyopathy in men: an tomorrow. Medical journals in transition—from author to
echocardiographic population screening study with a review reader, 195
of the death records, 499 Brander A. Ultrasound appearances in de Quervain’s subacute
Ahaneku JE, Taylor GO, Agbedana EO, Walker O, Sowunmi A, thyroiditis with long-term follow-up, 321
Salako LA. Effects of amlodipine on plasma lipid and Brinch L, see Evenson et al., 433
lipoprotein levels in hypertensive patients, 489 Brummer-Korvenkontios M, see Forslund et al., 87
Ahlborg BO, see Bolinder et al., 327 Brunner HR, see Burnier et al., 381
Ahonen J, see Ekstrand et al. 253 Burman P, see Ljunghall et al., 59; Johansson et al., 447
Aledort L. Editorial. Prophylaxis: the next haemophilia Burnier M, Waeber B, Brunner HR. First-line pharmacological
treatment, 1 treatment of hypertension, 381
Alvestrand A, see Gutierrez et al., 129
Andersen SJ, Arvidsson U, Fransson L, Nemcek K, Svensson Carlier B, see Delannoy et al., 457
S-E. The relationship between the transfer factor obtained at Carlson LA, see Johansson et al., 43
rest, and arterial oxygen tension during exercise in patients Chan JCN, Li PKT, Lai FM, Lai KN. Fatal adult
with miscellaneous pulmonary diseases, 415 Henoch-Schonlein purpura due to small intestinal infarction,
Andreasen PB, see Friis & Andreasen, 133 18]
Angelin B, see Ericsson et al., 313 Chen Y-DI, see Facchini et al., 267
Anttinen J, see Forslund et al., 87 Chen YN, see Facchini et al., 267
Arakawa M, see Gejyo & Arakawa, 531 Christensen CK, see Hansen et al., 161
Armellini F, see Zamboni et al., 341 Christiansen JS, see Hansen et al., 161
Arver S, see Bjorkholm et al., 443 Cock CC de, Visser FC, Roos JP, Van Eenige MJ. Reproducibility
Arvidson G, see Ronquist et al., 247 of symptom-limited exercise-stress testing performed 2 and 6
Arvidsson U, see Andersen et al., 415 weeks after myocardial infarction, 147
Aurell M, see Granerus et al., 15 Cohen AS. Minisymposium: Amyloidosis. History of
Auvinen §, see Forslund et al., 87 amyloidosis, 509
Colgan M, see Tyrell et al., 349
Bach D, see Maignan et al., 357 Colussi G, see Montoli et al., 535
Backman E, Henriksson KG. Treatment of congenital myotonia Cooke T, see Tyrell et al., 349
with sodium selenite and vitamin E, 376
Baynes RD, see Lapinsky et al., 273 de Boer WA, Tytgat GNJ. A patient with osteomalacia as single
Benson MD. Minisymposium: Amyloidosis. Familial presenting symptom of gluten-sensitive enteropathy, 81
amyloidosis, 525 de Faire U, see Nilsson et al., 397
Beran M, see Bjorkholm et al., 443 de Fooz C, see Delannoy et al., 457
Bergamo AIA, see Zamboni et al., 341 de Korwin J-D, see Maignan et al., 357
Bergin C, see Tyrell et al., 349 de Marchi M, see Zamboni et al., 341
Berglund L, see Ericsson et al., 313 de Vita S, Tavoni A, Jeracitano G, Gemignani G, Dolcher MP,
Bergqvist D, see Nordstrom et al., 155 Bombardieri S. Treatment of giant cell arteritis with
Bergstrom J, see Gutierrez et al., 129 cyclophosphamide pulses, 373
Bernow J, see Bondeson et al., 451 del Campo F, see Zamarron et al., 177
Berntorp E, see Nilsson et al., 25 Delannoy A, Hamels J, Mecucci C, Fally P, Wallef G, de Fooz C,
Billheden J, Settergren B, Stegmayr B, Juto P. Detection of Carlier B. Amylase-producing IgD-type multiple myeloma,
serum IgM antibodies to glomerular basement membrane in 457
two cases of nephropathia epidemica, 91 Delin, K, see Granerus et al., 15
Billstrom R, Lundquist A. Acute myelomonocytic leukaemia Devoy MAB, Tomson CRV, Edmunds ME, Feehally J, Walls J.
with infiltrative peripheral neuropathy, 193 Deterioration in renal function associated with angiotensin
Bjorkholm M, Pisa P, Arver S, Beran M. Haematologic effects of converting enzyme inhibitor therapy is not always reversible,
granulocyte-macrophage colony stimulating factor in a 493
patient with thiamazole-induced agranulocytosis, 443 Divine GW, see Koenig et al., 169
Bolinder GM, Ahlborg BO, Lindell JH. Use of smokeless tobacco: Dolcher MP, see de Vita et al., 373
blood pressure elevation and other health hazards found in Donatini B. Transient renal dysfunction in diabetic patients
large-scale population survey, 327 after IVIg therapy, 376
Bombardieri S, see de Vita et al., 373 Drosos AA, Sakkas LI, Goussia A, Siamopoulos KC,
Bondeson J, Ericsson U-B, Falke P, Mattiasson I, Nyman U, Moutsopoulos HM. Pulse cyclophosphamide therapy in
Lindell E, Bernow J. Tongue necrosis in temporal arteritis Wegener's granulomatosis: a pilot study, 279
provoked by ergotamine, 541 Dujardin P, see Taillan et al., 373
545
IMB 232
546 AUTHOR INDEX
Edlund A, see Straat et al., 53 cryoglobulinaemia and hepatitis C virus-related cirrhosis,
Edmunds ME, see Devoy et al., 493 284
Ejlertsen B, see Kristensen et al., 237 Gomes AJ, see Worman et al., 361
Ekstrand A, Groop L, Petterson E, Gronhagen-Riska C, Goussia A, see Drosos et al., 279
Laatikainen L. Matikainen E, Seppalainen A-M, Laasonen E, Granerus G, Aurell M, Delin K, Karlberg BE, Lorelius L-E. A
Summanen P, Ollus A, Ahonen J. Metabolic control and Swedish view on the diagnosis of renovascular hypertension,
progression of complications in insulin-dependent diabetic 15
patients after kidney transplantation, 253 Granfors K, see Saario et al., 73
Ericsson S, Eriksson M, Berglund L, Angelin B. Metabolism of Gronhagen-Riska C, see Ekstrand et al., 253
plasma low density lipoproteins in familial combined Groop L, see Ekstrand et al., 253
hyperlipidaemia: effect of acipimox therapy, 313 Grundy, SM, see Vega & Grundy, 405
Ericsson U-B, see Bondeson et al., 541 Gunnarsson K, see Ronquist et al., 247
Erikssen J, see Rollag et al., 299 Gutierrez A, Alvestrand A, Qureshi GA, Bergstrom H. Influence
Eriksson H, Welin L, Wilhemsen L, Larsson B, Ohlson L-O, of a meat-free diet on the urinary excretion of 3-
Svardsudd K, Tibblin G. Metabolic disturbances in methylhistidine and creatinine in chronic renal failure, 129
hypertension: results from the population study ‘Men born Gyntelberg F, see Hein et al., 471; 481
in 1913’, 389
Eriksson M, see Ericsson et al., 313 Hallgrimsson J, see Agnarsson et al., 499
Eriksson S, see Verbaan et al., 33 Halonen §S, see Rasanen et al., 305
Evensen SA, Brinch L, Stavem P, Tionnfjord G. Survival in 91 Hamels J, see Delannoy et al., 453
adults with acute myelogenous leukaemia treated with 1-6 Hamsten A, see Nilsson et al., 397
intensive courses of chemotherapy, 433 Hansen KW, Mau Pedersen M, Christensen CK, Schmitz A,
Christiansen JS, Mogensen CE. Normoalbuminuria ensures
Facchini F, Hollenbeck CB, Chen YN, Chen Y-DI, Reaven GM. no reduction of renal function in type 1 (insulin-dependent)
Demonstration of a relationship between white blood cell diabetic patients, 161
count, insulin resistance, and several risk factors for Hansson P. Coronary artery disease in Chinese males without
coronary heart disease in women, 267 hypercholesterolaemia, 287
Falke P, see Bondeson et al., 541 Harboe M, see Stavem & Harboe, 372
Fally P, see Delannoy et al., 457 Hardarson T, see Agnarsson et al., 499
Feehally J. see Devoy et al., 493 Harvald B. Quality assurance in internal medicine, 379
Feely J. see Tyrell et al., 349 Hayashi S, see Kihara et al., 353
Ferrari E, see Taillan et al., 37 3 Hein HO, Sorensen H, Suedicani P, Gyntelberg F. The Lewis
Ferrari P, see Taillen et al., 373 blood group—-a new marker of ischaemic heart disease, 481
Fischer-Colbrie R, see Wiedermann et al., 263 Hein HO, Suadicani P, Gyntelberg F Physical fitness or physical
Fletcher RH, Fletcher SW. Minisymposium: Medical activity as a predictor of ischaemic heart disease? A 17-year
journals—today and tomorrow. Medical journals and society: follow-up, 471
threats and responsibilities, 215 Henriksson KG. see Backman & Henriksson, 376
Fletcher RH, see Fletcher & Fletcher, 2 23 Henriksson P, see Straat et al., 53
Fletcher SW, see Fletcher & Fletcher, 2 15 Herold M, see Widermann et al., 263
Fletcher SW, Fletcher RH. Minisymposium: Medical Hippe E. see Jonsson et al., 185
journals—today and tomorrow. Responsibilities of medical Hojer J. Diagnosis of acute symptomatic aortic
journals to readers, 223 aneurysm—ultrasonography an important tool, 427
Floren CH, see Liao et al., 371 Hollenbeck CB, see Facchini et al., 267
Forslund T, Saltevo J, Anttinen J, Auvinen S, Brummer- Holmgaard SN, see Kristensen et al., 237
Korvenkontios M, Korhonen A, Poutiainen M. Complications Hulting A-L, Theodorsson E, Werner S. Thyrotropin-releasing
of nephropathia epidemica: three cases, 87 hormone increases serum levels of growth hormone-releasing
Fransson L, see Andersen et al., 415 hormone and growth hormone in patients with acromegaly,
Friis H, Andreasen PB. Drug-induced hepatic injury: an 229
analysis of 1100 cases reported to The Danish Committee on Husby G. Minisymposium: Amyloidosis. Nomenclature and
Adverse Drug Reactions between 1978 and 1987, 133 classification of amyloid and amyloidoses, 511
Frithz G, see Ronquist et al., 247 Hvarfner A, see Lind et al., 335
Fuzibet J-G, see Taillan et al., 373
Fyhrquist F, see Pettersson et al., 439 Ip JH, see Worman et al., 361
Ishii M, see Kihara et al., 353
Gejyo F, Arakawa M. Minisymposium: Amyloidosis. £,-
microglobulin-associated amyloidosis, 531 Jeracitano G, see de Vita et al., 373
Gemignani G, see de Vita et al., 373 Johanesen O, see Kapelrud et al., 453
Gertz MA. Minisymposium: Amyloidosis. Secondary amyloidosis Johansson AG, Burman P, Westermark K, Ljunghall S. The
(AA), 517 bone mineral density in acquired growth hormone deficiency
Glenner GG. Minisymposium: Amyloidosis. Alzheimer’s disease. correlates with circulating levels of insulin-like growth factor
533 I, 447
Goffin E, Oliveira DBG, Alexander GJM, Wreghitt T, Lockwood Johansson AG, see Ljunghall et al., 59
CM, Keogan M, Allain J-P. Association of type III Johansson J, Walldius G. & Carlson LA. Close correlation
AUTHOR INDEX 547
between high-density lipoprotein and triglycerides in Lee SS, Lawton JMW. Antimyeloperoxidase antibody in
normotriglyceridaemia, 43 systemic lupus erythematosus, 283
Jonsbu J, see Rollag et al., 299 Leino R, see Saario et al., 73
Jonsson V, Schroser HD, Trojaborg W, Staehelin Jensen T, Leinonen H, Naveri H, Toivonen L. Heart rate of physicians
Hippe E, Mork Hansen M. Autoimmune reactions in patients participating in the young investigators’ award competition,
with M-component and peripheral neuropathy, 185 285
Juhler M, see Kroll et al., 291 Lewis D, see Lapinsky et al., 273
Juto P, see Billheden et al., 91 Li PKT, see Chan et al., 181
Liao W, Lindgren S, Lindhagen T, Starck M, Floren CH. Plasma
endotoxin in patients with quiescent Crohn's disease, 371
Kampe O, see Ljunghal! et al., 59
Lind L, Hvarfner A, Pollare T, Lithell H, Ljunghall S. Fasting
Kapelrud H, Johannesen O, Oftebro H.
insulin, calcium metabolism and the electrocardiogram in
Testosterone/epitestosterone ratio in urine: a possible
hypertensive subjects, 335
diagnostic tool in the disclosure of exogenous testosterone
Lindblad B, see Nordstrom et al., 155
administration, 453
Lindell E, see Bondeson et al., 541
Karenko L, Pettersson T, Roberts P. Autosomal dominant
Lindell JH, see Bolinder et al., 327
‘Mediterranean fever’ in a Finnish family, 365
Linder S. Nobel seminar: Molecular medicine—cell biology in
Karlberg BE, see Graerus et al., 15
disease. Cancer and HIV: from viral genes to therapy? 3
Karlsson FA, see Ljunghall et al., 59
Lindgren S, see Verbaan et al., 33; Liao et al., 371
Kihara M, Kimura K, Yakuwa H, Minamisawa K, Hayashi S,
Lindh E, see Ljunghall et al., 59
Umemura S, Nihei T, Shionoiri H, Ishii M. Isolated left
Lindhagen T, see Liao et al., 371
coronary ostial stenosis as the sole arterial involvement in
Lindholm J, see Kroll et al., 291
Takayasu's disease, 353
Lindmark B, see Verbaan et al., 33
Kimura K, see Kihara et al., 353
Linzer M, see Koening et al., 169
Kisilevsky R. Minisymposium: Amyloidosis. Proteoglycans,
Lithell H, see Lind et al., 335
glycosaminoglycans, amyloid-enhancing factor, and amyloid
Ljunghall S, Johansson AG, Burman P, Kampe O, Lindh E,
deposition, 515
Karlsson FA. Low plasma levels of insulin-like growth factor
Kivinen P, see Rasanen et al., 305
1 (IGF-1) in male patients with idiopathic osteoporosis, 59
Kjellstrom T, see Nordstrom et al., 155
Ljunghall S, see Lind et al., 335: Johansson et al., 447
Kletchko S, see Nagappan & Kletchko, 77
Lock S. Minisymposium: Medical journals—today and
Knapp E, see Wiedermann et al., 263
tomorrow. Journalology; evolution of medical journals and
Koenig D, Linzer M, Pointinen M, Divine GW. Syncope in
some current problems, 199
young adults: evidence for a combined medical and
Lofqvist T, see Nilsson et al., 25
psychiatric approach, 169
Lorelius L-E, see Granerus et al., 15
Kok AME, see Mathus-Vliegen et al., 119
Lundquist A, see Billstrom & Lundquist, 193
Korhonen A, see Forslund et al., 87
Koski K, see Rasanen et al., 305
MacPhail AP, see Lapinsky et al., 273
Krarup-Hansen A, see Kristensen et al., 237
Maignan M, Wahl D, Thiacourt D, Bach D, de Korwin JD,
Kristensen B, Ejlertsen B, Holmegaard SN, Krarup-Hansen A,
Vaillant G, Paille F, Schmitt J. Self-limited primary
Transbol I, Mouridsen H. Prednisolone in the treatment of
cytomegalovirus colitis in an immunocompetent individual,
severe malignant hypercalcaemia in metastatic breast
357
cancer: a randomized study, 237
Mathus-Vliegen EMH, van der Voorde K, Kok AME, Res AMA.
Kroll M, Juhler M, Lindholm J. Hyponatraemia in acute brain
Dexfenfluramine in the treatment of severe obesity; a
disease, 291
placebo-controlled investigation of the effects on weight loss,
Kyle RA. Minisymposium: Amyloidosis. Introduction and
cardiovascular risk factors, food intake and eating behaviour,
overview, 507
119
Kyle RA. Minisymposium: Amyloidosis. Primary systemic
Matikainen E, see Ekstrand et al., 253
amyloidosis, 523
Mattiasson I, see Bondeson et al., 541
Mau Pedersen M, see Hansen et al., 161
Laakso M, see Mustonen et al., 65 Mecucci C, see Delannoy et al., 457
Laasonen E, see Ekstrand et al., 25 3 Mendelow B, see Lapinsky et al., 273
Laatikainen L see Ekstrand et al., 2 53 Metsarinne K, see Pettersson et al., 439
Lahesmaa R, see Saario et al., 73 Milani MP, see Zamboni et al., 341
Lai FM, see Chan et al., 181 Minamisawa K, see Kihara et al., 353
Lai KN, see Chan et al., 181 Minetti L, see Montoli et al., 535
Laitenen S, see Rasanen et al., 305 Mogensen CE, see Hansen et al., 161
Landou C, see Nilsson et al., 397 Montoli A, Colussi G, Minetti L. Hypercalcaemia in Addison's
Lansimies E. see Mustonen et al., 65 disease: calsiotropic hormone profile and bone histology, 535
Lapinsky SE, Baynes RD, Schulz EJ, MacPhail AP, Medelow B, Moore D, see Tyrell et al., 349
Lewis D, Bothwell TH. Anaemia, iron-related measurements Mork Hansen M, see Jonsson et al., 185
and erythropoietin levels in untreated patients with active Mouridsen H, see Kristensen, 237
leprosy, 273 Moutsopoulos HM, see Drosos et al., 279
Larsson B, see Eriksson et al., 389 Mustonen J, Uusitupa M, Lansimies E, Vainio P, Laasko M,
Lawton JMW, see Lee & Lawton, 283 Pyorala K. Autonomic nervous function and its relaticnship
548 AUTHOR INDEX
to cardiac performance in middle-aged diabetic patients Res AMA, see Mathus-Vliegen et al., 119
without clinically evident cardiovascular disease, 65 Riis P. Minisympsoium. Medical journals—today and
Mutanen M, see Rasanen et al., 305 tomorrow. New paradigms in journalology, 207
Riis P. Health promoting lifestyles—indeterminism versus
Nagappan R, Kletchko S. Bilateral emphysematous determinism, 289
pyelonephritis resolving to medical therapy, 77 Robbi R, see Zamboni et al., 341
Naveri H, see Leinonen et al., 285 Roberts P, see Karenko et al., 365
Nemcek K, see Andersen et al., 415 Rollag A, Jonsbu J, Aase O, Erikssen J. Standardized use of
Nihei T, see Kihara et al., 353 simple criteria from case history improves selection of
Nilsson IM, Bertorp E, Lofqvist T, Pettersson H. Twenty-five patients for cardiac-care unit (CCU) admission, 299
years’ experience of prophylactic treatment in severe Ronquist G, Frithz G, Gunnarsson K, Ardvison G. Decreased
haemophilia A and B, 25 erythrocyte cholesterol/phospholipid ratio in untreated
Nilsson J. The mevanolate pathway —a link between cellular patients with essential hypertension, 247
cholesterol homeostasis and growth regulation, 10 Roos JP, see de Cock et al., 147
Nilsson J, Volk-Jovinge S, Svensson J, Landou C, de Faire U, Rudnicki M, Transbol I. Increasing parathyroid hormone
Hamsten A. Association between high levels of growth concentrations in untreated primary hyperparathyroidism,
factors in plasma and progression of coronary 42]
atherosclerosis, 397 Ryberg B, see Nived et al., 461
Nissinen A, see Rasanen et al., 305
Nived O, Sturfelt G, Ryberg B. Two UV-induced episodes of Saario R, Leino R, Lahesmaa R, Granfors K, Toivanen A.
myelitis in a patient with systemic lupus erythematosus, 461 Function of terminal ileum patients with Yersinia-triggered
Nordenfelt E, see Verbaan et al., 33 arthritis, 73
Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A Sakkas LI, see Drosos et al., 279
prospective study of the incidence of deep-vein thrombosis Salako LA, see Ahaneku et al., 489
within a defined urban population, 155 Saltevo J, see Forslund et al., 87
Nyman U, see Bondeson et al., 451 Saltin B. Sedentary lifestyle: an underestimated health risk,
467
O'Dea K. Diabetes in Australian Aborigines: impact of the Schmitt J, see Maignan et al., 357
western diet and life style, 103 Schmitz A, see Hansen et al., 161
Oftebro H, see Kapelrud et al., 453 Schroder HD, see Jonsson et al., 185
Ohlson L-O, see Eriksson et al., 389 Schulz EJ, see Lapinsky et al., 273
Ollus A, see Ekstrand et al., 253 Seppalainen A-M, see Ekstrand et al., 253
Settergren B, see Billheden et al., 91
Paille F, see Wahl & Paille, 288; Maignan et al., 357 Shanik DHG, see Tyrell et al., 349
Paredes C, see Zamarron et al., 177 Shionoiri H, see Kihara et al., 353
Pekkanen J, see Rasanen et al., 305 Siamopoulos KC, see Drosos et al., 279
Pepys MB. Minisymposium: Amyloidosis. Amyloid P component Sigfusson N, see Agnarsson et al., 499
and the diagnosis of amyloidosis, 519 Skinner M. Minisymposium: Amyloidosis. Protein AA/SA, 513
Pesce A, see Taillan et al., 373 Smith U. Life style and genes—the key factors for diabetes and
Pettersen T, see Karenko et al., 365 the metabolic syndrome, 99
Petterson E, see Ekstrand et al., 2 Sorensen H, see Hein et al., 481
Pettersson H, see Nilsson et al., 2 Sowunmi A, see Ahaneku et al., 489
Petterson T, Metsarinne K, Teppo A-M, Fyhrquist F. Staelin Jensen T, see Jonsson et al., 185
Immunoreactive interleukin-6 in serum of patients with Starck M, see Liao et al., 371
f-lymphoproliferative diseases, 439 Stavem P, Harboe M. Does graft-violates-host disease give a
Pisa P, see Bjorkholm et al., 443 better indication of what goes on than graft-versus-host
Pointinen M, see Koenig et al., 169 disease, 372
Pollare T, see Lind et al., 335 Stavem P, see Evensen et al., 433
Poutiainen M, see Forslund et al., 87 Stegmayr B, see Billheden et al., 91
Pyorala K, see Mustonen et al., 65 Stengard J, see Rasanen et al., 305
Straat E, Edlund A, Henriksson P. Improved working capacity
Quaranta J-F, see Taillan et al., 373 in patients with ischaemic heart disease during a 10-day
Qureshi GA, see Gutierrez et al., 129 treatment with oral theophylline, 53
Sturfelt G, see Nived et al., 461
Rasanen L, Mutanen M, Pekkanen P, Laitinen S, Koski K, Suadicani P, see Hein et al., 471; 481
Halonen S, Kivinen P, Stengard J, Nissinen A. Dietary intake Summanen P, see Ekstrand et al., 253
of 70- to 89-year-old men in eastern and western Finland. Svardsudd K, see Eriksson et al., 389
305 Svensson J, see Nilsson et al., 397
Reaven GM. Coronary artery disease in Chinese males without Svensson S-E, see Andersen et al., 415
hypercholesterolaemia, 287
Reaven GM, see Facchini et al., 267 Taillen B, Ferrari P, Ferrari E, Fuzibet J-G, Pesce A, Quaranta
Reilly M, see Tyrell et al., 349 J-F, Dujardin P. Cryoglobulinaemia associated with hepatitis
Reinisch N, see Widermann et al., 263 C virus infection: a report of 13 cases, 372
AUTHOR INDEX 549
Tavoni A, see de Vita et al., 373 Visser FC, see Cock et al., 147
Taylor GO, see Ahaneku et al., 489 Volk-Jovinge S, see Nilsson et al., 397
Ten Harkel ADJ, Van Lieshout JJ, Wieling W. Treatment of Vollmar AM, see Wiedermann et al., 263
orthostatic hypotension with sleeping in the head-up tilt
position, alone and in combination with fludrocortisone, 139 Waeber B, see Burnier et al., 381
Tepper DC, see Worman et al., 361 Wahl D, see Maignan et al., 357
Teppo A-M, see Pettersson et al., 439 Wahl D, Paille F. Insulin sensitivity in alcoholics, 288
Theodorsson E, see Hulting et al., 229 Walker O, see Ahaneku et al., 489
Thiacourt D, see Maignan et al., 357 Walldius G, see Johansson et al., 43
Tibblin G, see Eriksson et al., 389 Wallef G, see Delannoy et al., 457
Tionnfjord G, see Evensen et al., 433 Walls J, see Devoy et al., 493
Todesco T, see Zamboni et al., 341 Welin L, see Eriksson et al., 389
Toivanen A, see Saario et al., 73 Werner S. see Hulting et al., 229
Toivonen L, see Leinonen et al., 285 Westermark K, see Johansson et al., 447
Tomson CRV, see Devoy et al., 493 Westermark P. Minisymposium: Amyloidosis. Polypeptide
Transbol I, see Kristensen et al., 237; Rudnicki & Transbol, hormones in amyloidosis, 529
421 Widell A, see Verbaan et al., 33
Trojaborg W, see Jonsson et al., 185 Wiedermann CJ, Reinisch N, Fischer-Colbrie R, Vollmar AM,
Tyrell T, Cooke T, Reilly M, Colgan M, Moore D, Shanik DG, Herold M, Knapp E. Proinflammatory cytokines in cardiac
Bergin C, Feely J. Lipoprotein (Lp(a)) and peripheral vascular myxomas, 263
disease, 349 Wieling W. see Ten Harke et al., 139
Tytgat GNJ, see de Boer & Tytgat, 81 Wilhelmsen L, see Eriksson et al., 389
Winters SL, see Worman et al., 361
Umemura §, see Kihara et al., 353 Worman Hj, Ip JH, Winters SL, Tepper DC, Gomes AJ.
Uusitupa M, see Mustonen et al., 65 Hypersensitivity reaction associated with acute hepatic
dysfunction following a single intravenous dose of
Vaillant G, see Maignan et al., 357 procainamide, 361
Vainio P, see Mustonen et al., 65
van der Voorde K, see Mathus-Vliegen et al., 119 Yakuwa H, see Kihara et al., 353
Van Eenige MJ, see de Cock et al., 147
Van Lieshout JJ, see Ten Harkel et al., 139 Zamboni M, Armellini F, Milani MP, Todesco T, de Marchi M,
Vega GL, Grundy SM. Occurrence of species of low-density Robbi R, Montresor G, Bergano AIA, Bosello O. Evaluation of
lipoprotein with defective clearance in patients with primary regional body fat distribution: comparison between W/H
moderate hypercholesterolaemia, 405 ration and computed tomography in obese women, 341
Verbaan H, Widell A, Lindgren S, Lindmark B. Nordenfelt E, Zammarron C, del Campo F, Paredes C. Extrinsic allergic
Eriksson S. Hepatitis C in chronic liver disease: an alveolitis due to exposure to esparto dust, 177
epidemiological study based on 566 consecutive patients
undergoing liver biopsy during a 10-year period, 33

Journal of Internal Medicine 1992; 232: 551-553
Subject Index
Acipimox, 313 Deep-vein thrombosis, 155
Acromegaly, 299 Dexfenfluramine, 119
Acute Diabetes mellitus, 65, 389
myelogenous leukaemia, 433 Diabetic nephropathy, 253
phase response, 273 Diagnosis, 299
symptomatic aortic aneurysm, 427 Diet, 305
Addison's disease bone histology, 535 Dietary survey, 305
Adverse drug reaction, 133 Differential diagnosis, 365, 427
Agranulocytosis, 443 Dyspnoea, 415
Amlodipine, 489
Amylase, 457 Eating behaviour, 119
Angina pectoris, 53 Echocardiography, 499
Angiography, 397 Elderly food consumption, 305
Angiotensin converting enzyme inhibitors, 493 Electrocardiography, 335
Anorectic drug, 119 Emphysematous pyelonephritis,
Anti GBM, 91 Empty cell sella syndrome, 91
Antiarrhythmic agents, 361 Epidemiology, 389
Arterial occlusive diseases, 493 Epitestosterone, 453
Atrial natriuretic peptide, 263, 291 Ergotamine, 54
Autoimmunity, 185 Erythrocyte membrane, 247
Autonomic Erythropoietin, 273
nervous function, 65 Exercise, 53
neuropathy, 65, 139 hypoxsaemia, 415
Autosomal dominant inheritance, 365 test, 65
testing, 147
Blood pressure, 139, 161, 327, 471
Body mass index, 327, 471, 481 Factor IX, 2
Bone mineral density, 59, 447 Factor VIII, 25
Brain disease, 291 Familial
combined hyperlipidaemia, 313
Calcium, 335 defective apolipoprotein B-100 (FDB), 405
Cardiac Mediterranean fever, 365
function, 65 Follow-up studies, 421
myxoma, 263 Functional impairment, 169
Cardiovascular
disease, 119, 327 Genetic epidemiology, 481
reflexes, 139 Giant-cell arteritis, 541
Carotid angiography, 541 Glomerula filtration rate, 161
Cerebral salt wasting syndrome, 291 Gluten-sensitive enteropathy (coeliac disease), 81
Chemotherapy, 433 Gradient gel electrophoresis (GGE), 43
Cholesterol, 247, 313, 481 Growth
Chronic factors, 397
liver disease, 33 hormone, 229, 447
lymphocytic leukaemia, 439 hormone deficiency, 447
Clinical epidemiology, 169 hormone-releasing hormone, 229
Colitis, 357 Guillain-Barré syndrome, 87
Computed tomography, 341
Coronary Haemophilia A, a5
artery disease, 397 Haemophilia B, 25
heart disease, 43, 267 Haemophiliac arthropathy, 25
stenosis, 353 Haemorrhagic fever, 91
Creatinine, 129 Haemotopoietic growth factors,
Cyclophosphamide, 279 HDL-cholesterol, 267
Cytogenetics, 457 Heart failure, 493
Cytokines, 263 Henoch-Schonlein purpura, 181
Cytomegalovirus, 357 Hepatic injury, 133
C-reactive protein, 27 Hepatitis C, 33
SUBJECT INDEX
Hepatocellular cancer, 33 Parathyroid hormone, 421
Hepatotoxicity, 361 Pathogenesis, 91
High-density lipoprotein (HDL) subclasses, 43 Peptic ulcer, 327
Hypercalcaemia, 237, 535 Peripheral
Hypercholesterolaemia, 405 neuropathy, 185
Hypersensitivity pneumonitis, 177 vascular disease, 349
Hypertension, 247, 335, 389, 493 Phlebography, 155
Hyperthyroidism, 443 Phospholipids, 247
Hypertrophic cardiomyopathy, 499 Physical
Hyponatraemia, 291 activity, 471
Hypopituitarism, 87 fitness, 471
Plasma-cell dyscrasia, 185, 439
IgD, 457 Polyneuropathy, 193
Immobilization, 237 Population
Incidence, 155 genetics, 481
Insulin, 267, 335, 389 screening, 499
Insulin-like growth factor, 1, 59, 47 Prednisolone, 237
Insulin-mediated glucose uptake, 267 Prevalence, 499
Interleukin-6, 263, 439 Primary hyperparathyroidism, 421
Ionized calcium, 421 Prophylaxis in haemophilia, 25
Iron-related measurement, 279 Pulse therapy, 279
Ischaemic heart disease, 53, 349, 471, 481 Puumala virus, 91
acute, 299
Reactive arthritis, 73
Kidney Reaven’s Syndrome X, 481
failure: acute, 493 Regional body fat distribution, 341
transplantation, 253 Renal
artery, obstruction, 493
Leukaemia, 193 biopsy, 91
Lewis blood group, 481 failure, 129
Lipids, 489 Reproducibility, 147
Lipoprotein (a), 349 RIBA, 2, 33
Lipoproteins, 489 Risk
Liver, 361 behaviour, 33
biopsy, 33 factors, 155
Low density Rupture, 427
lipoproteins, 313
lipoprotein (LDL), 405 Schilling test, 73
Serotoninergic drug, 119
MAG antibodies, 185 Sideroblasts, 279
Malabsorption, 81 Sjégren’s syndrome, 439
Meat-free diet, 129 Small intestinal infarction, 181
Medical therapy, 77 Smokeless, 327
‘Metabolic syndrome’, 389 Smoking, 327
Metastatic breast cancer, 237 Smooth muscle cells, 397
3-Methylhistidine, 129 Stipatosis, 177
Monoclonal gammopathy, 185 Subarachnoid haemorrhage, 291
Multiple myeloma, 439, 457 Survival, 237, 433
Myelitis, 461 Syncope, 169
Myocardial Systemic lupus erythematosus, 461
infarction, 147
ischaemia, 53 Takayasu's disease, 353
M-component, 185 Temporal arteritis, 541
Terminal ileum, 73
Na-K-ATPase inhibitors, 291 Testosterone, 453
Neoplasms, 321 Theophylline, 53
Neopterin, 263 Thiamazole, 443
Nephropathia epidemica, 91 Thyroid, 321
Nerve infiltration, 193 Thyroiditis, 321
Nutrients, 305 Thyrotropin-releasing hormone, 229
Tobacco, 327
Obesity, 119 Tongue necrosis, 541
Osteomalacia, 81 Transfer factor, 415
Osteoporosis, 59 Triglyceride, 43, 267
SUBJECT INDEX
Triglycerides, 313, 389, 481 Vitamin D, 81
Type 1 diabetes, 161 Voluntary reporting system, 133
Ultrasonography, 427 Waist-to-hip ratio, 341
Unstable angina, 353 Wegener’s granulomatosis, 279
Urinary albumin, 161 White cell count, 267
Virilism, 453 Yersinia, 73